Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
Status:
Completed
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
It is planned to explore the efficacy and safety of local 0.05% cyclosporine eye drops in the
treatment of chronic graft-versus-host eye disease. Through the comparative study with 0.1%
tacrolimus eye drops, to clarify the short-term and long-term efficacy of 0.05% CSA in these
patients, and to explore the benefits of long-term maintenance of local cyclosporine to
patients.